FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $56.66, for a total transaction of $2,245,775.76. Following the transaction, the chief executive officer now owns 2,955,614 shares of the company’s stock, valued at approximately $167,465,089.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
FibroGen Inc (NASDAQ:FGEN) opened at $57.50 on Monday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. The firm has a market cap of $4,726.33, a PE ratio of -28.19 and a beta of 1.74. FibroGen Inc has a 1 year low of $22.75 and a 1 year high of $63.00.
A number of large investors have recently modified their holdings of FGEN. California Public Employees Retirement System boosted its position in FibroGen by 2.2% during the second quarter. California Public Employees Retirement System now owns 93,200 shares of the biopharmaceutical company’s stock worth $3,010,000 after purchasing an additional 2,000 shares during the period. Parametric Portfolio Associates LLC boosted its position in shares of FibroGen by 44.2% in the second quarter. Parametric Portfolio Associates LLC now owns 14,590 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 4,470 shares during the period. Voya Investment Management LLC boosted its position in shares of FibroGen by 30.7% in the second quarter. Voya Investment Management LLC now owns 27,039 shares of the biopharmaceutical company’s stock valued at $873,000 after acquiring an additional 6,348 shares during the period. State Street Corp boosted its position in shares of FibroGen by 16.4% in the second quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock valued at $56,962,000 after acquiring an additional 248,922 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in shares of FibroGen in the second quarter valued at approximately $348,000. Hedge funds and other institutional investors own 59.24% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.